Cost–effectiveness analysis in pharmacogenomics

Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes

(2009) Stefan Vegter et al.   PHARMACOECONOMICS

A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

(2009) Lisa M. Meckley et al.   PHARMACOECONOMICS

Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism

(2009) Stefan Vegter et al.   Pharmacogenetics and Genomics

A Review of Public Policy Issues in Promoting the Development and Commercialization of Pharmacogenomic Applications: Challenges and Implications

(2008) Louis P. Garrison et al.   DRUG METABOLISM REVIEWS

Integration of Meta-analysis and Economic Decision Modeling for Evaluating Diagnostic Tests

(2008) Alexander J. Sutton et al.   MEDICAL DECISION MAKING

Exploring Uncertainty in Cost-Effectiveness Analysis

(2008) Karl Claxton   PHARMACOECONOMICS

The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

(2008) Josh J. Carlson et al.   VALUE IN HEALTH

Towards an economic evidence base for pharmacogenetics: consideration of outcomes is key

(2007) Katherine Payne   PHARMACOGENOMICS